Human epidermal growth factor receptor-2 (HER2) is a tyrosine kinase receptor involved in cell growth and differentiation. Targeting HER2 is a critical strategy in HER2-positive breast cancer treatment. Despite advancements in HER2-targeted therapies, drug resistance and side effects remain significant challenges. Therefore, identifying novel HER2 inhibitors with the potential to overcome resistance mechanisms while maintaining favorable drug-like properties is essential. Identifying novel HER2 inhibitors with high binding affinity and favorable drug-like properties is essential for overcoming these limitations. This study employed molecular docking and molecular dynamics simulations to evaluate the binding potential of plant-derived and synthetic compounds against HER2. The most promising candidates were further analyzed using ADMET profiling and binding free energy calculations to assess their drug-likeness and binding free energy. Among the tested compounds, axitinib, prunetin, and silymarin demonstrated strong HER2-binding affinities comparable to established inhibitors such as TAK-285 and lapatinib. Molecular dynamics simulations revealed that prunetin formed the most stable HER2-ligand complex, while axitinib exhibited the lowest binding free energy, indicating a strong interaction potential. ADMET analysis confirmed axitinib and prunetin as favorable drug candidates, whereas silymarin exhibited lower intestinal absorption. In conclusion, axitinib and prunetin emerged as promising HER2 inhibitors that may offer therapeutic advantages by addressing both drug resistance and toxicity concerns in HER2-positive breast cancer treatment. Prunetin, with its lower toxicity and higher stability, presents a safer therapeutic option, whereas axitinib offers high binding affinity. These findings suggest that these compounds could help overcome resistance and side effects associated with current HER2-targeted therapies.
21 February 2025 in Cell Biochemistry and Biophysics
Protein kinase B (AKT) isoforms are important kinases regulating fundamental biological processes such as cellular growth, metabolism, and apoptosis. Targeting these isoforms is critical for the development of therapeutic strategies in cancer. In this study, we evaluated 107 phytochemicals against AKT1, AKT2, and AKT3 using molecular docking, protein flexibility simulations, and ADMET profiling. Molecular docking revealed that isoangustone A (-9.8 kcal/mol) and lupalbigenin (-9.7 kcal/mol) exhibited stronger binding to AKT1 than the reference drug capivasertib (-9.2 kcal/mol). Cudraflavone B (-10.8 kcal/mol) and lupalbigenin (-10.4 kcal/mol) out performed capivasertib (-9.1 kcal/mol) against AKT2, while marein (-9.5 kcal/mol) and pristimerin (-9.4 kcal/mol) surpassed capivasertib (-8.9 kcal/mol) for AKT3. Protein flexibility analysis indicated stable ligand–protein complexes, and ADMET evaluation showed acceptable drug-likeness with some limitations, such as low Caco-2 permeability for certain compounds. These findings highlight promising lead compounds for AKT isoform inhibition; however, isoangustone A exhibits predicted hERG II inhibition, raising significant cardiotoxicity concerns that represent a major development barrier. The results are predictive and require in vitro cardiac safety profiling alongside in vivo validation before clinical advancement. Graphical abstract
This study aims identify plant-derived compounds that can inhibit glutathione peroxidase 4 (GPX4) enzyme and evaluate them through molecular docking, dynamics simulations, and ADMET analyses. The 3D structure of the GPX4 protein (PDB ID: 2OBI) was obtained from the Protein Data Bank. The plant-derived ligand library was compiled from the PubChem database and screened for compliance with Lipinski’s rules using ADMETLAB 2.0. Molecular docking simulations were performed using Autodock Vina. Molecular dynamics simulations of 100 nanoseconds were performed for the selected ligand–protein complexes using AMBER Tools and OpenMM software. The ADMET properties of the ligands were evaluated using the pKCSM web server. Compared to the reference inhibitor RSL3 (−7.2 kcal/mol), five plant compounds showed stronger binding affinity: withaferin A (−8.0 kcal/mol), mahanine (−7.9 kcal/mol), pseudobufarenogin (−7.8 kcal/mol), cucurbitacin I (−7.6 kcal/mol), and liquiritin (−7.5 kcal/mol). Molecular dynamics simulations showed that the complexes of withaferin A, mahanine, and liquiritin exhibited superior structural stability. ADMET analysis revealed that the compounds generally possess acceptable pharmacokinetic profiles but require some bioavailability optimization. The identified plant-derived compounds can be considered as potential therapeutic agents in cancer treatment by inducing ferroptosis via GPX4 inhibition. These findings provide an important basis for natural product-derived drug discovery studies.